Background Repetitive behaviours (RB) in patients with Gilles de la Tourette syndrome (GTS)
are frequent. However, a controversy persists whether they are manifestations of …

Objective In Parkinson disease (PD), the selective C‐O‐methyltransferase (COMT) inhibitor
entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its …

Studies of the phenotype and population distribution of rare genetic forms of parkinsonism
are required, now that gene‐targeting approaches for Parkinson disease have reached the …

Background A wide range of neurological manifestations has been described in COVID-19.
Methods In this nationwide retrospective observational study, patients in Tunisia diagnosed …

Objectives The LRRK2‐G2019S mutation is the most common cause of Parkinson's disease
(PD) in North Africa. G2019S‐PD has been described as similar to idiopathic with minor …

Objective: To assess the ability of potentially neuroprotective compounds to slow the
progression of Parkinson’s disease (PD), sensitive rating scales are needed to detect clinically …

Background In North African populations, G2019S mutation in LRRK2 gene, encoding for the
leucine-rich repeat kinase 2, is the most prevalent mutation linked to familial and sporadic …

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We
report on a 28‐year‐old man with severe coprolalia at the forefront of symptoms, which had a …

Genetic generalized epilepsies (GGE) (childhood absence epilepsy (CAE), juvenile myoclonic
epilepsy (JME) and epilepsy with generalized tonic-clonic seizures (GTCS)) are mainly …

Background. The prevalence of psychiatric disturbance for patients with multiple sclerosis (MS)
is higher than that observed in other chronic health conditions. We report three cases of …